Agenus | AGEN - Assets


Agenus reported $172.69M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Agenus USD 172.69M 13.76M Jun/2026
Amgen USD 96.05B 409M Sep/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Celldex Therapeutics USD 721.53M 60.82M Sep/2026
CSL USD 37.9B 1.5B Dec/2025
Eli Lilly USD 148.07B 5.79B Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Glaxosmithkline GBP 71.7B 8.83B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Intrexon USD 73.16M 77.88M Jun/2024
J&J USD 197.42B 3.64B Sep/2026
Jiangsu Hengrui CNY 76.72B 5.95B Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Merck EUR 52.69B 383M Jun/2026
Merck USD 132.77B 2.97B Sep/2026
Northwest Biotherapeutics USD 80.05M 49.44M Mar/2026
Novartis USD 117.15B 4.88B Sep/2026
Novavax USD 888M 67.57M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Veracyte USD 1.57B 86.89M Sep/2026